Home » NICE Shoots Down Sanofi’s Dupixent
NICE Shoots Down Sanofi’s Dupixent
Drugs Submissions and Approvals
The National Institute for Health Care and Excellence issued draft guidance recommending against National Health Service funding of Sanofi’s Dupixent (dupilumab) for treatment of severe atopic dermatitis.
NICE found the drug to be innovative for patients who need new treatments, agreeing it is a “step change” in the management of the skin disease, but expressed concerns about its cost-effectiveness.
NHS patients who were receiving treatment with the medication before the guidance was published will not be affected by the committee’s decision.